Literature DB >> 24684285

Thyroid nodules with atypia or follicular lesions of undetermined significance (Bethesda Category III): importance of ultrasonography and cytological subcategory.

Pedro Weslley Rosario1.   

Abstract

BACKGROUND: One possible result of fine-needle aspiration (FNA) in patients with thyroid nodules is "follicular lesion of undetermined significance" (FLUS) or "atypia of undetermined significance" (AUS). The risk of malignancy is relevant information to define appropriate management, and knowledge of predictors of malignancy in these nodules is therefore important. The objective of this prospective study was to evaluate clinical, laboratory, ultrasonographic, and cytological predictors of malignancy in patients with thyroid nodules and FLUS/AUS cytology.
METHODS: The sample consisted of 150 patients with thyroid nodules and an indication for FNA whose cytology was classified as FLUS/AUS according to the Bethesda classification criteria.
RESULTS: In the second FNA, cytology was nondiagnostic in 2 (1.3%) nodules and benign in 54 (36%), FLUS/AUS cytology persisted in 73 (48.6%), and cytology was suspicious for follicular neoplasm in 11 (7.3%) and for malignancy in 10 (6.6%). The rate of malignancy was 22.6%. Clinical and laboratory data or nodule size were not predictors of malignancy. The rate of malignancy was lower in nodules initially classified as FLUS (10.8% versus 41.3% with AUS). Ultrasonography (US) was also useful for predicting malignancy, with sensitivity, specificity, and positive and negative predictive values of 79.4%, 90.5%, 71%, and 93.75%, respectively. Different malignancy rates were obtained when the two parameters, cytological subcategory and US, were combined: (i) 3.9% for nodules nonsuspicious on US and FLUS, (ii) 11.4% for nonsuspicious nodules with AUS, (iii) 46.6% for suspicious nodules with FLUS, and (iv) 87% for suspicious nodules with AUS.
CONCLUSIONS: The combination of cytological subcategory (FLUS or AUS) and US provides different risks of malignancy for nodules initially classified as Bethesda category III.

Entities:  

Mesh:

Year:  2014        PMID: 24684285     DOI: 10.1089/thy.2013.0650

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  37 in total

1.  Usefulness of NRAS codon 61 mutation analysis and core needle biopsy for the diagnosis of thyroid nodules previously diagnosed as atypia of undetermined significance.

Authors:  Eun Kyung Jang; Won Gu Kim; Eui Young Kim; Hyemi Kwon; Yun Mi Choi; Min Ji Jeon; Jung Hwan Baek; Jeong Hyun Lee; Tae Yong Kim; Young Kee Shong; Jene Choi; Dong Eun Song; Won Bae Kim
Journal:  Endocrine       Date:  2015-11-07       Impact factor: 3.633

2.  Retrospective cytological evaluation of indeterminate thyroid nodules according to the British Thyroid Association 2014 classification and comparison of clinical evaluation and outcomes.

Authors:  Massimo Giusti; Barbara Massa; Margherita Balestra; Paola Calamaro; Stefano Gay; Simone Schiaffino; Giovanni Turtulici; Simonetta Zupo; Eleonora Monti; Gianluca Ansaldo
Journal:  J Zhejiang Univ Sci B       Date:  2017-07       Impact factor: 3.066

3.  The 5-tiered categorization system for reporting cytology is sufficient for management of patients with thyroid nodules compared to the 6-tiered Bethesda system.

Authors:  Jieun Koh; Hee Jung Moon; Eun-Kyung Kim; Jin Young Kwak; Jung Hyun Yoon
Journal:  Endocrine       Date:  2016-01-12       Impact factor: 3.633

4.  Cancer Risk Stratification of Indeterminate Thyroid Nodules: A Cytological Approach.

Authors:  Pablo Valderrabano; Laila Khazai; Zachary J Thompson; Marino E Leon; Kristen J Otto; Julie E Hallanger-Johnson; J Trad Wadsworth; Bruce M Wenig; Christine H Chung; Barbara A Centeno; Bryan McIver
Journal:  Thyroid       Date:  2017-09-14       Impact factor: 6.568

5.  Malignancy risk and characteristics of thyroid nodules with two consecutive results of atypia of undetermined significance or follicular lesion of undetermined significance on cytology.

Authors:  Vivian Youngjean Park; Eun-Kyung Kim; Jin Young Kwak; Jung Hyun Yoon; Hee Jung Moon
Journal:  Eur Radiol       Date:  2015-03-05       Impact factor: 5.315

Review 6.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

Review 7.  Thyroid follicular microcarcinoma.

Authors:  Andrea Casaril; Marco Inama; Harmony Impellizzeri; Matilde Bacchion; Mihail Creciun; Gianluigi Moretto
Journal:  Gland Surg       Date:  2020-01

8.  Malignancy is associated with microcalcification and higher AP/T ratio in ultrasonography, but not with Hashimoto's thyroiditis in histopathology in patients with thyroid nodules evaluated as Bethesda Category III (AUS/FLUS) in cytology.

Authors:  Oya Topaloglu; Husniye Baser; Fatma Neslihan Cuhaci; Nuran Sungu; Abdussamed Yalcin; Reyhan Ersoy; Bekir Cakir
Journal:  Endocrine       Date:  2016-05-12       Impact factor: 3.633

9.  Repeat fine-needle aspiration can be performed at 6 months or more after initial atypia of undetermined significance or follicular lesion of undetermined significance results for thyroid nodules 10 mm or larger.

Authors:  Jieun Koh; Eun-Kyung Kim; Jin Young Kwak; Jung Hyun Yoon; Hee Jung Moon
Journal:  Eur Radiol       Date:  2016-03-10       Impact factor: 5.315

10.  Cancer Risk Associated with Nuclear Atypia in Cytologically Indeterminate Thyroid Nodules: A Systematic Review and Meta-Analysis.

Authors:  Pablo Valderrabano; Laila Khazai; Zachary J Thompson; Susan C Sharpe; Valentina D Tarasova; Kristen J Otto; Julie E Hallanger-Johnson; J Trad Wadsworth; Bruce M Wenig; Christine H Chung; Barbara A Centeno; Bryan McIver
Journal:  Thyroid       Date:  2017-12-21       Impact factor: 6.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.